Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis

Overview

Journal Am J Clin Pathol

Publisher Oxford University Press

Specialty Pathology

Date 2021 Jun 4

PMID 34086841

Citations 8

Authors

Sruthi Babu

Nam W Kim

Maoxin Wu

Ina Chan

Luisa F Escobar-Hoyos

Kenneth R Shroyer

Affiliations

Soon will be listed here.

Abstract

Objectives: The microscopic features of urine cytology specimens are subjective and may not reliably distinguish between benign urothelial cells and low-grade urothelial carcinoma (UC). Prior studies demonstrated that keratin 17 (K17) detection in biopsies is highly sensitive for UC. The current study aimed to define K17 diagnostic test performance for initial screening and detect recurrent UC in urine specimens.

Methods: K17 was detected by immunocytochemistry (ICC) in consecutively collected urine specimens (2018-2019). A qualitative score for the K17 test was determined in 81 samples (discovery cohort) and validated in 98 samples (validation cohort). K17 sensitivity and specificity were analyzed in both cohorts across all grades of UC.

Results: Based on the discovery cohort, the presence of 5 or more K17 immunoreactive urothelial cells (area under the curve = 0.90; P < .001) was the optimal threshold to define a K17-positive test. The sensitivity of the K17 ICC test for biopsy-confirmed UC was 35 of 36 (97%) and 18 of 21 (86%) in the discovery and validation cohorts, respectively. K17 was positive in 16 of 19 (84%) specimens with biopsy-confirmed low-grade UC and in 34 of 34 (100%) of specimens with high-grade UC.

Conclusions: K17 ICC is a highly sensitive diagnostic test for initial screening and detection of recurrence across all grades of UC.

Citing Articles

Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.

Guo L, Cid A, Cucci J, Kunkel B, Defeis L, Matthews M BJUI Compass. 2024; 5(5):497-501.

PMID: 38751950 PMC: 11090771. DOI: 10.1002/bco2.338.

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.

Harsanyi S, Kianickova K, Katrlik J, Danisovic L, Ziaran S J Cancer Res Clin Oncol. 2024; 150(2):96.

PMID: 38372785 PMC: 10876723. DOI: 10.1007/s00432-024-05623-7.

Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.

Flores Monar G, Reynolds T, Gordon M, Moon D, Moon C Int J Mol Sci. 2023; 24(18).

PMID: 37762677 PMC: 10531979. DOI: 10.3390/ijms241814374.

Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.

Bosherz M, Samarska I, Gaisa N Methods Mol Biol. 2023; 2684:3-25.

PMID: 37410225 DOI: 10.1007/978-1-0716-3291-8_1.

"In the light of evolution:" keratins as exceptional tumor biomarkers.

Takan I, Karakulah G, Louka A, Pavlopoulou A PeerJ. 2023; 11:e15099.

PMID: 36949761 PMC: 10026720. DOI: 10.7717/peerj.15099.

References

Wang Y, Lang H, Yuan J, Wang J, Wang R, Zhang X . Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol. 2013; 34(3):1685-9. DOI: 10.1007/s13277-013-0703-5. View

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

Shariat S, Karam J, Lotan Y, Karakiewizc P . Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol. 2008; 10(2):120-35. PMC: 2483317. View

Hajdinjak T . UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008; 26(6):646-51. DOI: 10.1016/j.urolonc.2007.06.002. View

Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E . uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol. 2013; 121(7):392-7. DOI: 10.1002/cncy.21287. View

Escobar-Hoyos L, Yang J, Zhu J, Cavallo J, Zhai H, Burke S . Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol. 2013; 27(4):621-30. PMC: 4026928. DOI: 10.1038/modpathol.2013.166. View

Zippe C, Pandrangi L, Agarwal A . NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 1999; 161(1):62-5. View

Zellweger T, Benz G, Cathomas G, Mihatsch M, Sulser T, Gasser T . Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006; 119(7):1660-5. DOI: 10.1002/ijc.21704. View

Tan W, Rodney S, Lamb B, Feneley M, Kelly J . Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016; 47:22-31. DOI: 10.1016/j.ctrv.2016.05.002. View

10.

Rai S, Lali B, Venkataramana C, Philipose C, Rao R, Prabhu G . A Quest for Accuracy: Evaluation of The Paris System in Diagnosis of Urothelial Carcinomas. J Cytol. 2019; 36(3):169-173. PMC: 6592122. DOI: 10.4103/JOC.JOC_67_18. View

11.

Hosseini J, Golshan A, Mazloomfard M, Mehrsai A, Zargar M, Ayati M . Detection of recurrent bladder cancer: NMP22 test or urine cytology?. Urol J. 2012; 9(1):367-72. View

12.

Bai J, Babu S, Roa-Pena L, Hou W, Akalin A, Escobar-Hoyos L . Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. Hum Pathol. 2019; 94:40-50. DOI: 10.1016/j.humpath.2019.09.005. View

13.

Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W, Heidegger I . Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study. Int J Med Sci. 2017; 14(9):811-819. PMC: 5562188. DOI: 10.7150/ijms.19929. View

14.

Breen V, Kasabov N, Kamat A, Jacobson E, Suttie J, OSullivan P . A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol. 2015; 15:45. PMC: 4494166. DOI: 10.1186/s12874-015-0036-8. View

15.

Roa-Pena L, Leiton C, Babu S, Pan C, Vanner E, Akalin A . Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci Rep. 2019; 9(1):11239. PMC: 6677817. DOI: 10.1038/s41598-019-47519-4. View

16.

Lavery H, Zaharieva B, McFaddin A, Heerema N, Pohar K . A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection. BMC Cancer. 2017; 17(1):247. PMC: 5383950. DOI: 10.1186/s12885-017-3227-3. View

17.

Anbardar M, Monjazeb R . Reclassification of urinary cytology regarding The Paris System for Reporting Urinary Cytology with cytohistological correlation demonstrates high sensitivity for high-grade urothelial carcinoma. Diagn Cytopathol. 2020; 48(5):446-452. DOI: 10.1002/dc.24387. View

18.

Bosschieter J, Lutz C, Segerink L, Vis A, Zwarthoff E, Jeroen A van Moorselaar R . The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. Epigenomics. 2018; 10(5):673-687. DOI: 10.2217/epi-2017-0156. View

19.

Escobar-Hoyos L, Shah R, Roa-Pena L, Vanner E, Najafian N, Banach A . Keratin-17 Promotes p27KIP1 Nuclear Export and Degradation and Offers Potential Prognostic Utility. Cancer Res. 2015; 75(17):3650-62. DOI: 10.1158/0008-5472.CAN-15-0293. View

20.

Vlajnic T, Gut A, Savic S, Bubendorf L . The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH. J Clin Pathol. 2019; 73(2):90-95. DOI: 10.1136/jclinpath-2019-206109. View